Zymeworks Inc. (ZYME)

Market Cap	860.67M
Revenue (ttm)	76.30M
Net Income (ttm)	-122.70M
Shares Out	69.58M
EPS (ttm)	-1.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313,291
Open	12.59
Previous Close	12.51
Day's Range	12.21 - 12.56
52-Week Range	7.97 - 17.70
Beta	1.13
Analysts	Buy
Price Target	19.50 (+57.64%)
Earnings Date	Mar 5, 2025

About ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 28, 2017
• Employees: 286
• Stock Exchange: NASDAQ
• Ticker Symbol: ZYME
• Website: https://www.zymeworks.com

Financial Performance

In 2024, Zymeworks's revenue was $76.30 million, an increase of 0.38% compared to the previous year's $76.01 million. Losses were -$122.70 million, 3.39% more than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for ZYME stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 57.64% from the latest price.

Price Target

$19.5

(57.64% upside)

Analyst Consensus: Buy